Cargando…
Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial
BACKGROUND: Lung cancer is the main cause of cancer-related death in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Cisplatin and its derivatives are the first-line chemotherapeutic drugs for patients with advanced lung cancer, but the chemother...
Autores principales: | Zheng, Xing, Wang, Wenmin, Wang, Gefei, Liu, Shenghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284706/ https://www.ncbi.nlm.nih.gov/pubmed/34260519 http://dx.doi.org/10.1097/MD.0000000000025002 |
Ejemplares similares
-
How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial
por: Pan, Yi, et al.
Publicado: (2021) -
Acupuncture for blunt chest trauma: A protocol for a double-blind randomized control trial
por: Kao, Pei-Yu, et al.
Publicado: (2021) -
Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: A protocol for randomized, double-blind clinical study
por: Ding, ChunQin, et al.
Publicado: (2021) -
Efficacy and safety of Mudan granules for painful diabetic peripheral neuropathy: A protocol for a double-blind randomized controlled trial
por: Zhang, Aixia, et al.
Publicado: (2022) -
Effects of Shenfu injection on inflammatory factors and immune function in children with Mycoplasma pneumoniae: A protocol for a double-blind, randomized controlled trial
por: Pei, Honglian, et al.
Publicado: (2021)